Search

Your search keyword '"Zhang, Xu-Chao"' showing total 636 results

Search Constraints

Start Over You searched for: Author "Zhang, Xu-Chao" Remove constraint Author: "Zhang, Xu-Chao"
636 results on '"Zhang, Xu-Chao"'

Search Results

1. Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population

4. Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC

7. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial

9. Allelic Context of EGFR C797X–Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes

10. PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial

12. T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity

18. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets

19. Redox high phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma

21. Plasma EBV quantification is associated with the efficacy of immune checkpoint blockade and disease monitoring in patients with primary pulmonary lymphoepithelioma‐like carcinoma.

22. Plasma ddPCR for the detection of MET amplification in advanced NSCLC patients: a comparative real-world study

24. PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): a phase 2, randomized, controlled trial

25. Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

28. Allelic Context of EGFR C797X–Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes

29. Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer

33. Allelic Context of EGFRC797X–Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes

36. A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel

39. Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study

41. Genomic and immune characteristics ofHER2‐mutated non‐small cell lung cancer and response to immune checkpoint inhibitor‐based therapy

42. Heterogeneity in the immune microenvironment of bone metastasis in driver‐positive non‐small cell lung cancer

43. Supplementary Data from Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer

44. Data from Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer

45. Supplementary Table S2 from Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

46. Supplemental Figure 3 Functional validations of MET Y1248H and D1246N from Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

47. Supplemental Figure 2 Clonal progression of P02 and P04. from Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

48. Supplementary Figure Legends from Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation

49. Supplementary Figure S1 from Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

50. Supplementary Figure legends from Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Catalog

Books, media, physical & digital resources